Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07144462
EARLY_PHASE1
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NEUK203-215 Injection in Adult Chinese Patients With Relapsed/Refractory Autoimmune Diseases
Sponsor: Neukio Biotherapeutics (Shanghai) Co., Ltd.
View on ClinicalTrials.gov
Summary
The purpose of this study is to determine the safety, tolerability and preliminary efficacy of NEUK203-215 , a healthy donor (HD) allogeneic CD19/BCMA-targeted CAR-NK cell product, in participants with severe, refractory autoimmune diseases.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
8
Start Date
2025-09-04
Completion Date
2027-01-14
Last Updated
2025-08-27
Healthy Volunteers
No
Conditions
Interventions
DRUG
Fludarabine
Specified dose on specified days
DRUG
Cyclophosphamide (C)
Specified dose on specified days
GENETIC
NEUK203-215 Injection
Specified dose on specified days
Locations (1)
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China